Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]